Chronic Hepatitis B Therapeutics: Seven-Market Drug Forecast and Market Analysis

The report provides an in-depth assessment of the CHB therapeutics market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.

The hepatitis B virus (HBV) is a member of the Orthohepadnavirus genus, from the Hepadnaviridae family. HBV is transmitted through infected blood and body fluids, most commonly through unprotected sex and contaminated needles. HBV can also be transmitted from mother to child at birth, which is particularly common within highly endemic regions. Acute hepatitis B is a short-term illness that occurs within the first six months following HBV exposure. However, if the body fails to clear the virus after six months, chronic hepatitis B (CHB) virus infection occurs. CHB is specifically defined by the presence of hepatitis B surface antigen (HBsAg) in a patient's serum for at least six months. CHB is a lifelong disease for most patients, who are then at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC).

The analyst forecasts the global CHB marketplace-which, for the purposes of this report, comprises seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, Japan)-to experience growth during the forecast period. This growth will be driven primarily by the highly anticipated arrival of CHB functional cures, which include GSK's toll like receptor 8 agonist, bepirovirsen; Gilead Sciences' toll like receptor 8 agonist, selgantolimod; Aligos Therapeutics' capsid protein inhibitor, ALG-000184; and Arbutus Biopharma's HBV surface antigen inhibitor, imdusiran. Nevertheless, patent expiries, generic erosion across the 7MM, and reductions in the diagnosed prevalent cases are expected to curtail market growth.

Key Highlights

Report deliverables include a Pdf report and an Excel-based forecast model
Forecast includes the 7 major markets (7MM)
Forecast covers the period 2024-2034

Report Scope

Overview of CHB including etiology, pathophysiology and epidemiology.
Key topics covered include current market landscape, strategic competitor assessment, unmet needs and opportunities, R&D trends, pipeline assessment, and current and future players.
CHB therapeutics market outlook from 2024-2034, including annual cost of therapy per patient, and total sales revenues per product for each of the 7MM.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and identify the companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the 7MM CHB therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM CHB therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

1 Chronic Hepatitis B: Executive Summary

1.1 CHB market to experience growth from 2024-34
1.2 Gilead, GSK, Aligos, and Arbutus are key future players
1.3 Functional cure drugs are expected to address a major unmet need
1.4 Late-stage pipeline drugs will be a key driver of growth
1.5 What do physicians think?

2 Introduction

2.1 Catalyst

3 Disease Overview

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: total prevalent cases of CHB
4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CHB
4.4.5 Diagnosed prevalent cases of CHB by HBeAg status
4.4.6 Diagnosed prevalent cases of CHB by cirrhosis status
4.4.7 Diagnosed prevalent cases of CHB with cirrhosis by cirrhosis stage
4.4.8 Diagnosed prevalent cases of CHB segmented by both HBeAg and cirrhosis status
4.4.9 Treated diagnosed prevalent cases of CHB segmented by both HBeAg and cirrhosis status
4.5 Epidemiological forecast for CHB (2024-34)
4.5.1 Total prevalent cases of CHB
4.5.2 Age-specific total prevalent cases of CHB
4.5.3 Sex-specific total prevalent cases of CHB
4.5.4 Diagnosed prevalent cases of CHB
4.5.5 Age-specific diagnosed prevalent cases of CHB
4.5.6 Sex-specific diagnosed prevalent cases of CHB
4.5.7 Diagnosed prevalent cases of CHB by HBeAg status
4.5.8 Diagnosed prevalent cases of CHB by cirrhosis status
4.5.9 Diagnosed prevalent cases of CHB by cirrhosis stage
4.5.10 Diagnosed prevalent cases of CHB by HBeAg and cirrhosis status
4.5.11 Treated diagnosed prevalent cases of CHB by HBeAg and cirrhosis status
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 Limitations of the analysis
4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Development of a functional cure
7.3 Increased screening
7.4 Increased linkage to care
7.5 Awareness of preventative measures

8 R&D Strategies

8.1 Overview
8.1.1 Functional cure
8.1.2 Combination therapy
8.1.3 Novel drug classes
8.2 Clinical trials design
8.2.1 Endpoints
8.2.2 Inclusion/exclusion criteria
8.2.3 Combination therapies

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary Research - KOLs Interviewed for This Report
13.4.1 KOLs
13.5 Primary Research - Prescriber Survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Reviewers
13.6.5 Vice President of Disease Intelligence and Epidemiology
13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About the Analyst
Contact the Publisher

List of Tables

Table 1: Chronic hepatitis B: key metrics in the 7MM
Table 2: Phases of CHB infection
Table 3: Risk factors and comorbidities for CHB
Table 4: Treatment guidelines for chronic hepatitis B
Table 5: Top 10 deals by value, 2015-25
Table 6: CHB market - global drivers and barriers, 2024-34
Table 7: Key events impacting sales for CHB in the US, 2024-34
Table 8: CHB market - drivers and barriers in the US, 2024-34
Table 9: Key events impacting sales for CHB in the 5EU, 2024-34
Table 10: CHB market - drivers and barriers in the 5EU, 2024-34
Table 11: Key events impacting sales for CHB in Japan, 2024-34
Table 12: CHB market - drivers and barriers in Japan, 2024-34
Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

Figure 1: Sales forecast by country for CHB in 2024 and 2034
Figure 2: Analysis of the company portfolio gap in CHB during the forecast period
Figure 3: Competitive assessment of the CHB pipeline drugs benchmarked against the SOC, Vemlidy
Figure 4: Hepatitis B virus structure
Figure 5: Key steps in HBV replication and potential therapeutic targets
Figure 6: 7MM, total prevalence of CHB, men and women, %, all ages, 2014-34
Figure 7: 7MM, diagnosed prevalence of CHB, men and women, %, all ages, 2014-34
Figure 8: 7MM, sources used to forecast the total prevalent cases of CHB
Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of CHB
Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of CHB by HBeAg status
Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of CHB with and without cirrhosis
Figure 12: 7MM, sources used to forecast the diagnosed prevalent cases of CHB by cirrhosis type
Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of CHB by both HBeAg and cirrhosis status
Figure 14: 7MM, total prevalent cases of CHB, N, both sexes, all ages, 2024
Figure 15: 7MM, total prevalent cases of CHB by age, N, both sexes, 2024
Figure 16: 7MM, total prevalent cases of CHB by sex, N, all ages, 2024
Figure 17: 7MM, diagnosed prevalent cases of CHB, N, both sexes, all ages, 2024
Figure 18: 7MM, diagnosed prevalent cases of CHB by age, N, both sexes, 2024
Figure 19: 7MM, diagnosed prevalent cases of CHB by sex, N, all ages, 2024
Figure 20: 7MM, diagnosed prevalent cases of CHB by HBeAg status, N, both sexes, all ages, 2024
Figure 21: 7MM, diagnosed prevalent cases of CHB by cirrhosis status, N, both sexes, all ages, 2024
Figure 22: 7MM, diagnosed prevalent cases of CHB with cirrhosis segmented by cirrhosis stage, N, both sexes, all ages, 2024
Figure 23: 7MM, diagnosed prevalent cases of CHB by HBeAg status and cirrhosis status, N, both sexes, all ages, 2024
Figure 24: 7MM, treated diagnosed prevalent cases of CHB by HBeAg status and cirrhosis status, N, both sexes, all ages, 2024
Figure 22: CHB treatment algorithm
Figure 26: Unmet needs and opportunities in CHB
Figure 27: Overview of the development pipeline in CHB
Figure 28: Key late-stage trials for the promising pipeline agents that the analyst expects be licensed for CHB in the 7MM during the forecast period
Figure 29: Competitive assessment of the CHB pipeline drugs benchmarked against the SOC, Vemlidy
Figure 30: Analysis of the company portfolio gap in CHB during the forecast period
Figure 31: Global (7MM) sales forecast by country for CHB in 2024 and 2034
Figure 32: Sales forecast by drug for CHB in the US in 2024 and 2034
Figure 33: Sales forecast by drug for CHB in the 5EU in 2024 and 2034
Figure 34: Sales forecast by drug for CHB in Japan in 2024 and 2034

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Gilead Sciences
Aligos Therapeutics
GSK
Arbutus Biopharma

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€16040EUR$17,995USD£13,910GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€32080EUR$35,990USD£27,821GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€48120EUR$53,985USD£41,731GBP

Key Highlights

Report Scope

Reasons to Buy

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

Chronic Hepatitis B (CHB): Epidemiology Forecast to 2034

Entecavir Market Size, Forecast, and Market Insight - 2032

ASC22 Market Size, Forecast, and Emerging Insight - 2032

Hepatitis B Vaccine Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

Chronic Hepatitis B - Market Insight, Epidemiology And Market Forecast - 2032